Disclaimer: This content is for informational and educational purposes only and should not be construed as financial or investment advice. Always do your own research and consult a licensed financial advisor before making investment decisions.

Disclosure: The author does not hold a position in NTLA.

← Back to Free Index

NTLA

Analysis as of: 2026-07-21

Intellia Therapeutics, Inc.

Intellia Therapeutics develops gene-editing medicines for severe inherited diseases, led by programs in hereditary angioedema and ATTR amyloidosis.

biotech healthcare

On Yahoo Finance ...

Jump to: Summary • Analysis • Opportunity • Risk • Trends • LE Structure • Third Party Analyst Consensus

Summary

From Clinical Proof to Franchise Test

The upside here is mostly a conversion story: clinical success becoming regulatory approval, payer access, and product revenue. A good HAE launch can create a durable rerate, but the path is still narrow, sequential, and highly sensitive to execution.

Analysis

Thesis

If lonvo-z reaches market on the 2027 path and proves a credible launch, Intellia can re-rate from cash-burning platform biotech to rare-disease franchise, with non-linear upside from first-mover trust, reusable human editing data, and renewed ATTR option value by 2031.

Last Economy Alignment

AI helps Intellia design edits and learn faster, but value still depends on hard-to-automate clinical proof, manufacturing, and FDA trust.

Upgrade to Allocator to also access: Thesis Critique

Opportunity Outlook

Average Implied 5-Year Multiple

4.0x (from 5 most recent analyses)

Reasoning

This is mainly a conversion story: a first product can turn platform credibility into real revenue and a much broader investor base. If lonvo-z launches well, Intellia stops being valued like a binary science project and starts being valued like a rare-disease company with reusable know-how. I do not assume a top-tier premium because first-launch, concentration, and regulatory baggage still matter.

Upgrade to Allocator to also access: Simplified Opportunity Explanation

Risk Assessment

Overall Risk Summary

This is no longer mainly a science-risk story; it is a regulatory-and-launch conversion story. The biggest risks are BLA slippage or review friction, slower-than-expected HAE uptake for a first irreversible therapy, ATTR failing to restore second-franchise credibility, and continued burn forcing dilution before commercial proof is established.

Upgrade to Allocator to also access: Tech Maturity Risk Score, Adoption Timing Risk Score, Moat Strength Risk Score, Capital Needs Risk Score, Regulatory Risk Score, Execution Risk Score, Concentration Risk Score, Unit Economics Risk Score, Valuation Risk Score, Macro Sensitivity Risk Score

Trends

Key Changes

No material clinical, regulatory, or financing update has been posted in the last 7-10 days; the latest IR item remains a routine July 6 inducement grant notice.
The upcoming-events page still shows no scheduled event, so near-term repricing remains more likely to come from BLA progress than conference commentary.
The thesis is still anchored to the June 13 lonvo-z Phase 3 update and the May 11 guidance to complete the rolling BLA in 2H 2026.

Upgrade to Builder to also access: Future Considerations

Last Economy Structure

AI Industrial Score

0.31

They control rare human editing data and the regulatory package for what could be the first in vivo CRISPR launch, so each clinical win can make the next program easier. But AI does not remove the real bottlenecks here: FDA trust, long-term safety, and reliable manufacturing.

Upgrade to Reader to also access: Score Decomposition, Confidence Level

Upgrade to Allocator to also access: Obsolescence Vectors, Pricing Fragility

Upgrade to Reader to also access: Constraint Benefit Score, Obsolescence Risk Score

Third Party Analyst Consensus

12-Month Price Target

$24.86

Upgrade to Reader to also access: Bull Case, Base Case, Bear Case

Next Arc Research